Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117753

Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism.

B Månsson, D Carey, M Alini, M Ionescu, L C Rosenberg, A R Poole, D Heinegård, and T Saxne

Department of Rheumatology, Lund University, Sweden.

Find articles by Månsson, B. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Carey, D. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Alini, M. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Ionescu, M. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Rosenberg, L. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Poole, A. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Heinegård, D. in: PubMed | Google Scholar

Department of Rheumatology, Lund University, Sweden.

Find articles by Saxne, T. in: PubMed | Google Scholar

Published March 1, 1995 - More info

Published in Volume 95, Issue 3 on March 1, 1995
J Clin Invest. 1995;95(3):1071–1077. https://doi.org/10.1172/JCI117753.
© 1995 The American Society for Clinical Investigation
Published March 1, 1995 - Version history
View PDF
Abstract

Serum concentrations of specific cartilage and bone molecules reflecting tissue turnover were measured in two well-defined patient groups with early rheumatoid arthritis with distinctly different disease outcome to see if early differences in their levels are prognostic of the rate of joint destruction. Compared with a matched normal population, increased concentrations of cartilage oligomeric matrix protein (COMP) were found in all patients who developed rapid hip joint destruction. In contrast, levels of a putative marker of cartilage aggrecan synthesis, the chondroitin sulfate epitope 846, were increased only in patients with slow joint destruction. Levels of bone sialoprotein (BSP) were increased in both groups, as were levels of the C-propeptide of type II procollagen (CPII), a marker of collagen II synthesis. The increased concentrations of the 846 epitope in patients with slow joint destruction suggest increased aggrecan synthesis. The low levels of the 846 epitope in patients with rapid joint destruction, concomitant with elevated levels of CPII, suggest a selective increase in collagen synthesis. The elevated BSP levels indicate an increased bone turnover in both groups. Thus elevated serum levels of COMP may indicate an unfavorable prognosis for rapid joint destruction, whereas elevated 846 epitope indicates a more favorable prognosis.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1071
page 1071
icon of scanned page 1072
page 1072
icon of scanned page 1073
page 1073
icon of scanned page 1074
page 1074
icon of scanned page 1075
page 1075
icon of scanned page 1076
page 1076
icon of scanned page 1077
page 1077
Version history
  • Version 1 (March 1, 1995): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts